X

Trial Profile

A Phase I Safety and Pharmacodynamic Study of Intravenous Infusion of PLX-PAD Cells in Patients With PAH

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 04 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Emiplacel (Primary)
Indications Pulmonary arterial hypertension
Focus Adverse reactions
Sponsors United Therapeutics Corporation

Most Recent Events

13 Mar 2023 According to a Pluristem Therapeutics media release, Pluristem Therapeutics has changed its name to Pluri Inc.
16 Feb 2016 Status changed from recruiting to discontinued as per ClinicalTrials.gov record.
08 Dec 2015 According to a Pluristem Therapeutics Inc. media release, the company announced positive data from 1 cohort of PLX-PAD used for the treatment of Pulmonary Arterial Hypertension.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com